7 analysts have shared their evaluations of OptimizeRx OPRX during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 5 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 3 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.0, a high estimate of $17.00, and a low estimate of $13.00. Surpassing the previous average price target of $14.25, the current average has increased by 5.26%.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive OptimizeRx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Constantine Davides | JMP Securities | Maintains | Market Outperform | $16.00 | $16.00 |
Constantine Davides | JMP Securities | Raises | Market Outperform | $16.00 | $15.00 |
David Grossman | Stifel | Maintains | Buy | $13.00 | $13.00 |
Constantine Davides | JMP Securities | Maintains | Market Outperform | $15.00 | - |
Constantine Davides | JMP Securities | Announces | Market Outperform | $15.00 | - |
David Grossman | Stifel | Maintains | Buy | $13.00 | $13.00 |
Sean Dodge | RBC Capital | Maintains | Outperform | $17.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OptimizeRx. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of OptimizeRx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on OptimizeRx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into OptimizeRx's Background
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
OptimizeRx: A Financial Overview
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 51.43% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OptimizeRx's net margin is impressive, surpassing industry averages. With a net margin of -35.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of -5.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): OptimizeRx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: OptimizeRx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.